This week we examine more of your responses regarding GLP-1 therapy…. See more GLP-1 Agonist Resources. I was glad to see that almost everyone realized that when a GLP-1 agonist is added to a sulfonylurea that it is not the GLP-1 agonist that is responsible for any side effects. It’s …

This week in Part 3 of our Case Study, Mr. Walker and his wife return for a follow-up visit as his glucose control has not improved as much as expected. Click here to see if you agree with the drug choice. In our analysis of the GLP-1 survey data, we …

Exenatide, a GLP-1 receptor agonist, improves glycemic control and body weight with twice daily or once weekly subcutaneous (SC) injections in patients with type 2 diabetes (T2DM)….

Type 2 diabetes mellitus (T2DM) often requires combination therapy to maintain glycemic control. Adding a sulfonylurea to metformin therapy improves glycemic control, but can cause hypoglycemia and weight gain. This 2-yr double-blind trial investigated the long-term efficacy and safety of adding linagliptin or glimepiride to ongoing metformin to treat T2DM….

Exenatide yields beta cell improvement and weight loss in individuals with diabetes but has not been well-studied in individuals with prediabetes….

This randomized, open-label, parallel-group, multicenter, 24-wk main treatment study, followed by a variable extension of at least 52 wk, compared the efficacy and safety of lixisenatide 20 µg QD and exenatide 10 µg BID in 634 T2DM patients insufficiently controlled on metformin ≥1.5 g/day (mean age 57.4 yr, diabetes duration …

The cardiovascular (CV) benefit of glucose lowering, particularly if too intensive, in type 2 diabetes mellitus (T2DM) is currently debated. Some modalities have even been reported, unexpectedly, to be associated with worse CV outcomes. To investigate the CV profile of the novel DPP-4 inhibitor linagliptin, a pre-specified meta-analysis of all …

Edited by Trisha Dunning AM, RN, MEd, PhD, CDE, FRCNA and Glenn Ward MBBS, BSc, DPhil (Oxon), FRACP, FRCPath   Mr. KM was referred to a diabetes center by his GP. Mr. KM is a 77-year-old man who has had type 2 diabetes for 17 years: current HbA1c 9.5%; random …

This week’s Homerun Slides cover eye diseases including Efferent Cranial Neuropathy, Glaucoma, AION and Retinal Vascular Occlusion….

This week I picked up my new glasses and was chatting with the optometrist about how many of his patients have diabetes. Dr. Adler sees a good number of them as his population is a little older and what surprises him is that they often make no connection between diabetes and …